1. Home
  2. NEXN vs AKBA Comparison

NEXN vs AKBA Comparison

Compare NEXN & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NEXN
  • AKBA
  • Stock Information
  • Founded
  • NEXN 2007
  • AKBA 2007
  • Country
  • NEXN Israel
  • AKBA United States
  • Employees
  • NEXN N/A
  • AKBA N/A
  • Industry
  • NEXN Computer Software: Programming Data Processing
  • AKBA Biotechnology: Pharmaceutical Preparations
  • Sector
  • NEXN Technology
  • AKBA Health Care
  • Exchange
  • NEXN Nasdaq
  • AKBA Nasdaq
  • Market Cap
  • NEXN 636.1M
  • AKBA 729.1M
  • IPO Year
  • NEXN 2021
  • AKBA 2014
  • Fundamental
  • Price
  • NEXN $8.58
  • AKBA $3.10
  • Analyst Decision
  • NEXN Strong Buy
  • AKBA Strong Buy
  • Analyst Count
  • NEXN 9
  • AKBA 5
  • Target Price
  • NEXN $14.00
  • AKBA $6.90
  • AVG Volume (30 Days)
  • NEXN 508.6K
  • AKBA 2.6M
  • Earning Date
  • NEXN 11-14-2025
  • AKBA 11-06-2025
  • Dividend Yield
  • NEXN N/A
  • AKBA N/A
  • EPS Growth
  • NEXN N/A
  • AKBA N/A
  • EPS
  • NEXN 0.75
  • AKBA N/A
  • Revenue
  • NEXN $371,746,000.00
  • AKBA $203,733,000.00
  • Revenue This Year
  • NEXN $5.43
  • AKBA $43.91
  • Revenue Next Year
  • NEXN N/A
  • AKBA $32.09
  • P/E Ratio
  • NEXN $11.45
  • AKBA N/A
  • Revenue Growth
  • NEXN 9.65
  • AKBA 16.75
  • 52 Week Low
  • NEXN $6.93
  • AKBA $1.52
  • 52 Week High
  • NEXN $12.60
  • AKBA $4.08
  • Technical
  • Relative Strength Index (RSI)
  • NEXN 43.37
  • AKBA 58.35
  • Support Level
  • NEXN $8.49
  • AKBA $2.93
  • Resistance Level
  • NEXN $8.79
  • AKBA $3.18
  • Average True Range (ATR)
  • NEXN 0.35
  • AKBA 0.14
  • MACD
  • NEXN 0.03
  • AKBA 0.03
  • Stochastic Oscillator
  • NEXN 39.68
  • AKBA 82.92

About NEXN Nexxen International Ltd. American Depository Shares

Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and advanced TV that helps empower advertisers, agencies, digital publishers and broadcasters to achieve desired outcomes, including increased efficiency and returns, across the media supply chain. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. Company operates in America, APAC, EMEA, regions, with majority revenue from America.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: